In Papua New Guinea, 1500+ women die every year from childbirth-related causes – 80 times higher than in Australia. And these deaths are, mostly, preventable.
Your support will help stop preventable deaths of mothers and babies in PNG
One of the leading causes of mortality and morbidity globally, malaria was responsible for around 435,000 deaths and 216 million clinical cases in 2017. An estimated 3.2 billion people are at risk of the disease, with young children and pregnant women most affected.
A two-way pipeline will be created where our research discoveries can be tested in the field, and field programs inform discovery research through our long-standing connections with vulnerable target populations, especially in Papua New Guinea and Myanmar.
Through this program, Burnet will contribute to:
reaching the WHO elimination targets of a 90 percent reduction in malaria incidence and mortality through an active program of basic, discovery and translational research and in-field education, prevention and treatment programs.
supporting country programs in our region that assist WHO in reaching targets of elimination in at least 35 countries by 2030.
Deputy Director (People); Head of Malaria Immunity and Vaccines Laboratory; Adjunct Professor Monash University
Antibody engineering to study responses mediating protective immunity
This project will involve engineering antibodies against malaria parasite proteins.
Clinical studies on malaria
The negative consequences of malaria and how to prevent them in children and pregnant women.
Decision science using Optima
Research and applications across disease areas to improve allocative efficiency.
Developing new antimalarial drugs that block protein trafficking
Developing new antimalarial drugs that block protein trafficking and host cell modification.
Developing vaccines against malaria
This project aims to identify key antigens and specific epitopes that are targets of protective immunity.
Discovering the mechanisms and targets of immunity against malaria
Identifying the key targets of protective immunity in people who live in malaria-endemic regions.
Evaluating a highly sensitive rapid malaria diagnostic in PNG
HS-RDT MiP in PNG: Testing performance of a novel high sensitivity rapid diagnostic malaria test in pregnant women.
Evaluation of Malaria Case-Based Reporting using a mobile phone application in Myanmar
Evaluating the effectiveness of a mobile phone-based application to improve the reporting and surveillance of malaria in Myanmar
Functional antibody responses to malaria vaccine candidates
Understanding how functional immunity develops to potential malaria vaccine candidates.
Host and parasite factors that predict Artemisinin Resistance reservoirs
Understanding how population immunity seeds transmission of malaria infectious reservoirs, including drug resistant parasites
Host red blood cell modification sustains the virulence of malaria parasites
Understanding how malaria parasites modify their human host cells to inform new antimalarials.
Immunity against unstructured proteins in malaria
Assessing the importance of immune responses directed against unstructured proteins from Plasmodium species.
Immunity to malaria and infectious diseases during pregnancy
How are pregnant women affected by infectious diseases such as malaria?
Immunity, drug efficacy and spread of antimalarial drug resistance
Identifying immune biomarkers to predict antimalarial efficacy is essential.
Impact of declining transmission on immunity and risk of malaria rebound
As malaria transmission falls, it is critical to understand how changing immunity affects risk of malaria.
Major advances in understanding malaria immunity and biology
Identifying key targets of immunity, the mechanisms mediating immunity, and how it is acquired.
Mechanism of antimalarial drug action
Understanding how blood-stage replication of Plasmodium could be targeted by vaccines and novel drugs.
Optimal community-delivered malaria elimination models for the Greater Mekong Sub-region
Developing an elimination model that is acceptable, operational, and cost-effective across GMS countries
Predicting quality and potency of monoclonal and natural antibodies
Rapid, simple and scalable assays for predicting antibody potency.
Serological surveillance to identify mosquito exposure and malaria transmission
Identifying and understanding “hot spots” and “hot pops” of malaria transmission are crucial to target interventions for elimination.
Vaccines against Plasmodium vivax and P. falciparum malaria
This involves identifying and prioritising candidate antigens for vaccine development.
31 July, 2019
Burnet’s Associate Professor Leanne Robinson has been nominated for a Australian Museum Eureka Prize.
17 July, 2019
Specialised videos by Burnet Institute scientists of malaria parasite invasion have validated Oxford research to develop a world-first vaccine.
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2019 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.
